Core Viewpoint - The innovative product matrix for aortic in-situ window branch reconstruction, developed by the National Cardiovascular Disease Center and Xianjian Technology, has received approval from the National Medical Products Administration (NMPA), marking a significant advancement in the field and setting a new standard for in-situ window technology [1][5]. Group 1: Product Overview - The product matrix includes the Ankura Plus in-situ window branch reconstruction main stent and the CSkirt adaptive anti-leak branch stent, creating a comprehensive "three-in-one" solution for aortic branch reconstruction [1][4]. - The innovative product has undergone a clinical study involving 120 patients with Stanford type B aortic dissection, demonstrating its safety and effectiveness in providing precise and leak-proof treatment options [5][6]. Group 2: Technical Advantages - The ISF technology is widely adopted due to its anatomical compatibility, moderate technical difficulty, and high patency rates, making it a preferred choice for treating aortic diseases [4][6]. - The Ankura Plus main stent features a customized opening area and a high success rate of 97.5% for immediate procedures, enhancing surgical efficiency and precision [6][7]. - The CSkirt branch stent incorporates a self-adaptive sealing design that minimizes the risk of leaks, with a reported type III leak rate of only 1.8% after one year [6][7]. Group 3: Market Position and Future Plans - Xianjian Technology aims to lead the industry by providing a complete solution for aortic endovascular repair, covering key technical areas such as arch branch, visceral branch, and iliac artery reconstruction [8][12]. - The company plans to continue collaborating with clinical experts to advance vascular health technologies and enhance China's core competitiveness in cardiovascular interventions [13].